journal
MENU ▼
Read by QxMD icon Read
search

Journal of Neuro-oncology

journal
https://www.readbyqxmd.com/read/28643151/multi-institutional-external-validation-of-a-novel-glioblastoma-prognostic-nomogram-incorporating-mgmt-methylation
#1
Jason K Molitoris, Yuan James Rao, Rajal A Patel, Liam T Kane, Shahed N Badiyan, Haley Gittleman, Jill S Barnholtz-Sloan, Soren M Bentzen, Tim J Kruser, Jiayi Huang, Minesh P Mehta
A recent nomogram for glioblastoma (GBM) was designed to incorporate methylguanine-DNA methyltransferase (MGMT) methylation status in trial patients receiving temozolomide. Since clinical trial patients are strictly selected, compared to the general population, we performed a multi-institutional, external, independent assessment of the nomogram. Consecutive adult patients with supratentorial GBM diagnosed between June 2007 and December 2014 who initiated TMZ-based concurrent chemoradiotherapy (CRT) and were not enrolled on RTOG 0525 or 0825 were eligible...
June 22, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28643150/epigenetically-controlled-six3-expression-regulates-glioblastoma-cell-proliferation-and-invasion-alongside-modulating-the-activation-levels-of-wnt-pathway-members
#2
Baoxin Zhang, Chenfu Shen, Fengyun Ge, Tingting Ma, Zuping Zhang
Glioma is the most common primary brain tumor in adults. Six3 is a human homologue of the highly conserved sine oculis gene family and essential transcription regulatory factor in process of eye and fetal forebrain development. However, little is known about the role of Six3 in human tumorigenesis. The aim of this study is to investigate the methylation/expression of Six3 and reveal its function and action mechanism in glioma. Our results showed that Six3 was down-regulated in human glioma tissues and human glioma SHG-44, U251, SF126 and U373-MG cells compared with the normal tissues...
June 22, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28639133/stereotactic-biopsy-in-elderly-patients-risk-assessment-and-impact-on-treatment-decision
#3
Stephanie G Kellermann, Christina A Hamisch, Daniel Rueß, Tobias Blau, Roland Goldbrunner, Harald Treuer, Stefan J Grau, Maximilian I Ruge
To evaluate risk profile, diagnostic yield and impact on treatment decision of stereotactic biopsy (SB) in elderly patients with unclear cerebral lesions. In this single center retrospective analysis we identified all patients aged ≥70 years receiving SB between January 2005 and December 2015. Demographic data, Karnofsky Performance Status (KPS), histology, comorbidity (by CHA2DS2-VASc Score) and use of anticoagulation were retrieved. We scrutinized diagnostic yield, procedural complications (mortality, transient and permanent morbidity), hospitalization time and therapeutic consequence...
June 21, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28631192/leptomeningeal-carcinomatosis-9-years-after-nodule-resection-for-pulmonary-carcinoma-in-situ-mrs-and-pathological-studies
#4
LETTER
Yiqi Lin, Fei Yuan, Sheng Chen
No abstract text is available yet for this article.
June 19, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28631191/effect-of-angiotensin-system-inhibitors-on-survival-in-newly-diagnosed-glioma-patients-and-recurrent-glioblastoma-patients-receiving-chemotherapy-and-or-bevacizumab
#5
Victor A Levin, James Chan, Meenal Datta, Jennie L Yee, Rakesh K Jain
Given prior studies that suggest the use of angiotensin system inhibitors (ASIs) is associated with prolonged overall survival (OS) in glioblastoma (GBM) patients, we evaluated the effect of ASIs in glioma patients receiving chemotherapy and/or bevacizumab (BEV). Using retrospective IRB-approved electronic chart review of newly diagnosed WHO grade 2-4 glioma patients from the Kaiser Permanente Tumor Registry of Northern California, we evaluated the impact of ASIs on OS by Cox proportional hazard model analysis for subgroups who received cytotoxic therapy, cytotoxic therapy with BEV, or BEV alone, as well as those with recurrent GBM (rGBM)...
June 19, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28623604/craniospinal-irradiation-for-treatment-of-metastatic-pediatric-low-grade-glioma
#6
Derek S Tsang, Erin S Murphy, Sharon E Ezell, John T Lucas, Christopher Tinkle, Thomas E Merchant
Patients with disseminated pediatric low-grade glioma (LGG) initially treated with chemotherapy frequently experience disease progression, with 5-year event-free survival (EFS) of <20% and 10-year overall survival (OS) of approximately 70%. This study aimed to describe outcomes of metastatic pediatric LGG treated with craniospinal irradiation (CSI). A retrospective study was performed of all patients with metastatic pediatric LGG treated with CSI at a single institution. EFS was defined as survival without disease progression or secondary high-grade glioma...
June 17, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28620836/sox2-immunity-and-tissue-resident-memory-in-children-and-young-adults-with-glioma
#7
Juan C Vasquez, Anita Huttner, Lin Zhang, Asher Marks, Amy Chan, Joachim M Baehring, Kristopher T Kahle, Kavita M Dhodapkar
Therapies targeting immune checkpoints are effective in tumors with a high mutation burden that express multiple neo-antigens. However, glial tumors including those seen in children carry fewer mutations and there is an unmet need to identify new antigenic targets of anti-tumor immunity. SOX2 is an embryonal stem cell antigen implicated in the biology of glioma initiating cells. Expression of SOX2 by pediatric glial tumors and the capacity of the immune system in these patients to recognize SOX2 has not been previously studied...
June 15, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28597184/epithelial-membrane-protein-2-emp2-promotes-angiogenesis-in-glioblastoma-multiforme
#8
Yu Qin, Masamichi Takahashi, Kristopher Sheets, Horacio Soto, Jessica Tsui, Panayiotis Pelargos, Joseph P Antonios, Noriyuki Kasahara, Isaac Yang, Robert M Prins, Jonathan Braun, Lynn K Gordon, Madhuri Wadehra
Glioblastoma multiforme (GBM) is the most aggressive malignant brain tumor and is associated with an extremely poor clinical prognosis. One pathologic hallmark of GBM is excessive vascularization with abnormal blood vessels. Extensive investigation of anti-angiogenic therapy as a treatment for recurrent GBM has been performed. Bevacizumab, a monoclonal anti-vascular endothelial growth factor A (VEGF-A), suggests a progression-free survival benefit but no overall survival benefit. Developing novel anti-angiogenic therapies are urgently needed in controlling GBM growth...
June 9, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28593402/clinical-presentation-and-prognostic-indicators-in-100-adults-and-children-with-neurofibromatosis-1-associated-non-optic-pathway-brain-gliomas
#9
Susan Byrne, Steve Connor, Karine Lascelles, Ata Siddiqui, Darren Hargrave, Rosalie E Ferner
Type 1 Neurofibromatosis (NF1) is a common autosomal dominant condition, with a major impact on the nervous system, eye, bone, and skin, and a predisposition to malignancy. At present it is not possible to predict clinically or on imaging, whether a brain tumour will remain indolent or undergo high-grade change. There are no consensus guidelines on the follow-up of non-optic pathway glioma (non-OPG) tumours in NF1. One hundred patients from the National NF1 Service with generalised NF1 and a diagnosis of non-OPG glioma were followed up for a median time of 63 months after glioma detection...
June 7, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28589424/molecular-landscape-of-pediatric-diffuse-intrinsic-pontine-gliomas-about-22-cases
#10
LETTER
R El Ayoubi, B Boisselier, A Rousseau
No abstract text is available yet for this article.
June 6, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28577033/impact-of-acute-hematological-toxicity-on-treatment-interruptions-during-cranio-spinal-irradiation-in-medulloblastoma-a-tertiary-care-institute-experience
#11
Narendra Kumar, Raviteja Miriyala, Pragyat Thakur, Renu Madan, Pravin Salunke, Budhi Yadav, Ankita Gupta
To analyze treatment interruptions due to acute hematological toxicity in patients of medulloblastoma receiving cranio-spinal irradiation (CSI). Prospectively collected data from case records of 52 patients of medulloblastoma treated between 2011 and 2014 was evaluated. Blood counts were monitored twice a week during CSI. Spinal irradiation was interrupted for patients with ≥grade 2 hematological toxicity and resumed after recovery to grade 1 level (TLC >3000; platelet count >75,000). Treatment interruptions and hematological toxicity were analyzed...
June 2, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28577032/advancements-in-the-study-of-mirna-regulation-during-the-cell-cycle-in-human-pituitary-adenomas
#12
REVIEW
Ting Zhang, Zijiang Yang, Heng Gao
Pituitary adenomas (PAs), single-clone adenomas arising from pituitary gland cells, comprise one of the most frequent tumors found in the sella region. The prevalence of PAs is approximately 15%, third only after gliomas and meningioma among intracranial tumors. Autopsy and radiological analysis found that the incidence of PAs is approximately 22.5%. Most PAs are benign, although a few are malignant. Just 0.1% of patients with PAs develop pituitary carcinoma. However, owing to mass effects and unregulated secretion of pituitary hormones, PAs also lead to serious morbidity...
June 2, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28577031/natural-history-of-optic-pathway-gliomas-in-a-cohort-of-unselected-patients-affected-by-neurofibromatosis-1
#13
Eva Trevisson, Matteo Cassina, Enrico Opocher, Virginia Vicenzi, Marta Lucchetta, Raffaele Parrozzani, Giacomo Miglionico, Rodica Mardari, Elisabetta Viscardi, Edoardo Midena, Maurizio Clementi
Optic pathway glioma (OPG) represents the most common central nervous system tumor in children with Neurofibromatosis type-1 (NF1). Although overall survival is usually good, no clear prognostic factors have been identified so far. We assessed the natural history of OPG in a cohort of unselected patients affected by NF1. We retrospectively evaluated 414 consecutive patients affected by NF1 and referred to our NF1 clinic before age 6. Average follow-up was 11.9 years: 52 out of 414 patients had OPG with a total cumulative incidence of 15...
June 2, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28577030/stereotactic-radiosurgery-for-small-brain-metastases-and-implications-regarding-management-with-systemic-therapy-alone
#14
Daniel M Trifiletti, Colin Hill, Or Cohen-Inbar, Zhiyuan Xu, Jason P Sheehan
While stereotactic radiosurgery (SRS) has been shown effective in the management of brain metastases, small brain metastases (≤10 mm) can pose unique challenges. Our aim was to investigate the efficacy of SRS in the treatment of small brain metastases, as well as elucidate clinically relevant factors impacting local failure (LF). We utilized a large, single-institution cohort to perform a retrospective analysis of patients with brain metastases up to 1 cm in maximal dimension. Clinical and radiosurgical parameters were investigated for an association with LF and compared using a competing risk model to calculate cumulative incidence functions, with death and whole brain radiotherapy serving as competing risks...
June 2, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28567590/evaluation-of-outcomes-after-stereotactic-radiosurgery-for-pilocytic-astrocytoma
#15
Daniel M Trifiletti, M Sean Peach, Zhiyuan Xu, Ronald Kersh, Timothy N Showalter, Jason P Sheehan
Pilocytic astrocytomas are rare intracranial gliomas that are typically treated with surgical extirpation. Our aim was to report the radiologic and clinical outcomes of patients treated with stereotactic radiosurgery (SRS) for pilocytic astrocytoma in the primary and salvage setting. Patients with pilocytic astrocytoma treated at a single institution with SRS from 1990 to 2015 were reviewed. Patient, disease, and treatment characteristics were collected and overall survival, local control, and toxicity were evaluated...
May 31, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28567589/early-tumor-growth-between-initial-resection-and-radiotherapy-of-glioblastoma-incidence-and-impact-on-clinical-outcomes
#16
Javier E Villanueva-Meyer, Seunggu J Han, Soonmee Cha, Nicholas A Butowski
Early tumor growth, or increased contrast-enhancing tumor not related to evolving post-surgical injury, in the interval between surgical resection and initiation of radiotherapy has implications for treatment planning and clinical outcomes. In this study we evaluated the incidence of early tumor growth, correlated tumor growth with survival outcome measures, and assessed predictors of early tumor growth in glioblastoma. We reviewed the records of patients with newly-diagnosed glioblastoma who underwent surgical resection and chemoradiotherapy at our institution...
May 31, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28567588/immunotherapy-and-radiation-in-glioblastoma
#17
REVIEW
Solmaz Sahebjam, Andrew Sharabi, Michael Lim, Pravin Kesarwani, Prakash Chinnaiyan
Radiation therapy plays a central role in the management of glioblastoma. Although primarily thought of as modality to provide local tumor control through DNA damage, the capacity of ionizing radiation to modulate tumor immune response has long been recognized. The recent emergence of clinically active immunotherapies offers exciting potential for harnessing the immune modulatory effects or radiation through combinatorial strategies designed to enhance clinical outcomes. In this Review, we provide background describing the unique immune environment within the central nervous system, how ionizing radiation may modulate the tumor immune response, preclinical and clinical data testing the combination of radiation and immune modulating agents, and highlight some of the current challenges in extending these findings clinically...
May 31, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28567587/estimating-the-annual-frequency-of-synchronous-brain-metastasis-in-the-united-states-2010-2013-a-population-based-study
#18
Courtney Kromer, Jordan Xu, Quinn T Ostrom, Haley Gittleman, Carol Kruchko, Raymond Sawaya, Jill S Barnholtz-Sloan
Brain metastases (BM) are one of the most common types of brain tumors and are a relatively common event in the disease process for several high-incidence cancer types, including breast and lung cancers. Historically, information on metastases including BM have not been collected as part of national cancer registration in the US, but BM at time of primary cancer diagnosis (SBM), is now collected by the National Cancer Institute's (NCI) Surveillance, Epidemiology, and End Results (SEER) system. Using data from 18 SEER registries from 2010 to 2013, we assessed the frequency of SBM at time of primary diagnosis in the US by site, histology group, sex, race, age, and insurance status...
May 31, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28567586/tumor-related-neurocognitive-dysfunction-in-patients-with-diffuse-glioma-a-systematic-review-of-neurocognitive-functioning-prior-to-anti-tumor-treatment
#19
REVIEW
Emma van Kessel, Anniek E Baumfalk, Martine J E van Zandvoort, Pierre A Robe, Tom J Snijders
Deficits in neurocognitive functioning (NCF) frequently occur in glioma patients. Both treatment and the tumor itself contribute to these deficits. Data about the role of the tumor are scarce, because NCF has mostly been studied postoperatively. We aimed to summarize data on pre-treatment NCF in glioma patients and to determine the overall and domain-specific prevalence of neurocognitive dysfunction. We searched PubMed and Embase according to PRISMA-P protocol for studies that evaluated pre-treatment NCF in glioma patients (1995-November 2016) and extracted information about NCF...
May 31, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28560665/radiation-agent-combinations-for-glioblastoma-challenges-in-drug-development-and-future-considerations
#20
REVIEW
Charles A Kunos, Evanthia Galanis, Jeffrey Buchsbaum, Qian Shi, Lewis C Strauss, C Norman Coleman, Mansoor M Ahmed
Glioblastoma is an aggressive disease characterized by moderate initial response rates to first-line radiation-chemotherapy intervention followed by low poor response rates to second-line intervention. This article discusses novel strategic platforms for the development of radiation-investigational agent combination clinical trials for primary and recurrent glioblastoma in a NCI-NCTN settings with simultaneous analysis of challenges in the drug development process.
May 30, 2017: Journal of Neuro-oncology
journal
journal
28661
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"